<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5627917</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0185640</article-id><article-id pub-id-type="publisher-id">PONE-D-17-24019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Tropical Diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Actinobacteria</subject><subj-group><subject>Mycobacterium Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Tuberculosis Diagnosis and Management</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Host transcriptional responses following <italic>ex vivo</italic> re-challenge with <italic>Mycobacterium tuberculosis</italic> vary with disease status</article-title><alt-title alt-title-type="running-head">Gene expression after <italic>M</italic>. <italic>tuberculosis</italic> re-challenge</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Elaine A.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>John</surname><given-names>Serene H.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tablante</surname><given-names>Elizabeth C.</given-names></name><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Christine A.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kenneth</surname><given-names>John</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Russell</surname><given-names>David G.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3788-0665</contrib-id><name><surname>Mehta</surname><given-names>Saurabh</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Division of Nutritional Sciences, Cornell University, Ithaca, New York, United States</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Division of Infectious Diseases, St. John&#x02019;s Research Institute, Bangalore, Karnataka, India</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York, United States</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Institute for Nutritional Sciences, Global Health, and Technology, Cornell University, Ithaca, New York, United States</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Neyrolles</surname><given-names>Olivier</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Institut de Pharmacologie et de Biologie Structurale, FRANCE</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>E.A.Y., S.H.J., C.A.K., E.C.T., D.G.R., and J.K. have no conflicts of interest. S.M. is an unpaid board member of a diagnostic start-up focused on developing assays for low-cost and point-of-care measurement of certain nutrients from a drop of blood using results from his research as a faculty member at Cornell University. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p></fn><corresp id="cor001">* E-mail: <email>smehta@cornell.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>4</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>10</issue><elocation-id>e0185640</elocation-id><history><date date-type="received"><day>24</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Yu et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Yu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0185640.pdf"/><abstract><p>The identification of immune correlates that are predictive of disease outcome for tuberculosis remains an ongoing challenge. To address this issue, we evaluated gene expression profiles from peripheral blood mononuclear cells following <italic>ex vivo</italic> challenge with <italic>Mycobacterium tuberculosis</italic>, among participants with active TB disease (ATBD, n = 10), latent TB infection (LTBI, n = 10), and previous active TB disease (after successful treatment; PTBD, n = 10), relative to controls (n = 10). Differential gene expression profiles were assessed by suppression-subtractive hybridization, dot blot, real-time polymerase chain reaction, and the comparative cycle threshold methods. Comparing ATBD to control samples, greater fold-increases of gene expression were observed for a number of chemotactic factors (CXCL1, CXCL3, IL8, MCP1, MIP1&#x003b1;). ATBD was also associated with higher IL1B gene expression, relative to controls. Among LTBI samples, gene expression of several chemotactic factors (CXCL2, CXCL3, IL8) was similarly elevated, compared to individuals with PTBD. Our results demonstrated that samples from participants with ATBD and LTBI have distinct gene expression profiles in response to <italic>ex vivo M</italic>. <italic>tuberculosis</italic> infection. These findings indicate the value in further characterizing the peripheral responses to <italic>M</italic>. <italic>tuberculosis</italic> challenge as a route to defining immune correlates of disease status or outcome.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>National Institute of Allergy and Infectious Diseases (US)</institution></funding-source><award-id>AI118582</award-id><principal-award-recipient><name><surname>Russell</surname><given-names>David G.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>T32-DK007158</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Elaine A.</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Cornell University, Mario Einaudi Center for International Studies (South Asia Program)</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3788-0665</contrib-id><name><surname>Mehta</surname><given-names>Saurabh</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Cornell University, Human Ecology Alumni Association</institution></funding-source><principal-award-recipient><name><surname>Yu</surname><given-names>Elaine A.</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution>Cornell University, Graduate School</institution></funding-source><principal-award-recipient><name><surname>Yu</surname><given-names>Elaine A.</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution>Cornell University, Division of Nutritional Sciences</institution></funding-source><principal-award-recipient><name><surname>Yu</surname><given-names>Elaine A.</given-names></name></principal-award-recipient></award-group><funding-statement>Research reported in this publication was supported by the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases; T32-DK007158 award); the Mario Einaudi Center for International Studies (South Asia Program), Human Ecology Alumni Association, Graduate School, Division of Nutritional Sciences at Cornell University (for E.A.Y. research and travel support). D.G.R. is supported by National Institutes of Health (National Institute of Allergy and Infectious Diseases; AI118582 award). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, or the National Institutes of Health.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="9"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data are available in the eCommons repository at Cornell University (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7298/X4JH3JBN">https://doi.org/10.7298/X4JH3JBN</ext-link>).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data are available in the eCommons repository at Cornell University (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7298/X4JH3JBN">https://doi.org/10.7298/X4JH3JBN</ext-link>).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Globally, 10.4 million incident cases of active tuberculosis (TB) disease (ATBD) and 1.4 million TB-related deaths were reported in 2015 [<xref rid="pone.0185640.ref001" ref-type="bibr">1</xref>]. Over the past century, anti-TB drugs, bacille Calmette-Gu&#x000e9;rin (BCG) vaccination, and public health strategies such as directly observed treatment, have contributed to a reduction in TB-related mortality [<xref rid="pone.0185640.ref001" ref-type="bibr">1</xref>]. However, latent TB infection (LTBI) and recurrent ATBD remain critical issues for global control [<xref rid="pone.0185640.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0185640.ref002" ref-type="bibr">2</xref>], particularly given that previous anti-TB treatment is an established risk factor for drug resistance [<xref rid="pone.0185640.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0185640.ref004" ref-type="bibr">4</xref>].</p><p>Determining the contribution of <italic>Mycobacterium tuberculosis</italic> re-infection, as opposed to reactivation, is a challenge for numerous TB control programs, especially in endemic areas [<xref rid="pone.0185640.ref005" ref-type="bibr">5</xref>]. <italic>M</italic>. <italic>tuberculosis</italic> re-infection can occur at any time during ATBD and LTBI, and is independent of relapse [<xref rid="pone.0185640.ref005" ref-type="bibr">5</xref>]. Moreover, the inability of vaccination to protect against <italic>M</italic>. <italic>tuberculosis</italic> re-infection and reactivation represent significant gaps in research and therapeutics [<xref rid="pone.0185640.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0185640.ref008" ref-type="bibr">8</xref>]. The sole approved vaccine BCG and vaccines in the development pipeline are largely protective against ATBD [<xref rid="pone.0185640.ref009" ref-type="bibr">9</xref>], and not LTBI or exogenous <italic>M</italic>. <italic>tuberculosis</italic> re-infection [<xref rid="pone.0185640.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0185640.ref010" ref-type="bibr">10</xref>]. Currently there is no approved and effective vaccine for individuals with LTBI [<xref rid="pone.0185640.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0185640.ref010" ref-type="bibr">10</xref>].</p><p>The assessment of vaccine efficacy hinges on identifying biomarkers predictive of disease progression and outcomes [<xref rid="pone.0185640.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0185640.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0185640.ref012" ref-type="bibr">12</xref>]. Given the numerous constraints for TB vaccine development, it has been hypothesized that identification of peripheral correlates of protective immunity against <italic>M</italic>. <italic>tuberculosis</italic> may be more realistic, compared to a single biomarker [<xref rid="pone.0185640.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0185640.ref015" ref-type="bibr">15</xref>]. A unique transcriptional signature has been identified for ATBD; this whole-blood transcript signature was associated with disease severity and observed to resolve after treatment [<xref rid="pone.0185640.ref016" ref-type="bibr">16</xref>]. The extent to which this signature is predictive rather than diagnostic still needs to be determined. Previous studies have argued that differential gene expression was associated with TB disease recurrence, susceptibility, and host control [<xref rid="pone.0185640.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0185640.ref019" ref-type="bibr">19</xref>]. Little is known regarding transcriptional biomarkers of post-primary <italic>M</italic>. <italic>tuberculosis</italic> re-infection or even enhanced exposure due to reactivation, despite the public health significance.</p><p>Distinguishing gene expression patterns following <italic>ex vivo</italic> challenge with <italic>M</italic>. <italic>tuberculosis</italic> among individuals with ATBD, LTBI, previous active TB disease (PTBD; after successful treatment) has significance in identifying diagnostic and predictive biomarkers, which are required for development of vaccines and therapeutics [<xref rid="pone.0185640.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0185640.ref021" ref-type="bibr">21</xref>]. Our study objective involved delineating patient responses to the <italic>ex vivo</italic> challenge of <italic>M</italic>. <italic>tuberculosis</italic> through analysis of the relative gene expression profiles between study participants with ATBD, LTBI, PTBD, compared to controls.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Ethical conduct of research</title><p>The Institutional Ethics Review Committees at St. John&#x02019;s Medical College and Hospital (St. John&#x02019;s National Academy of Health Sciences; Bangalore, Karnataka, India) and Arogyavaram Medical Centre (Arogyavaram, Andhra Pradesh, India) approved the study protocol. Study participants provided voluntary informed consent prior to data collection.</p></sec><sec id="sec004"><title>Study population</title><p>Study participants (n = 40) were enrolled at a hospital outpatient department (St. John&#x02019;s Medical College and Hospital, Bangalore, Karnataka) in India. Participants included four groups of patients with ATBD (n = 10) and LTBI (n = 10), PTBD (n = 10), and controls (n = 10). Inclusion criteria included TB status (defined below), and BCG vaccination. Exclusion criteria included: age (&#x02264; 14 years), HIV infection (GS HIV Combo Ag/Ab EIA; Bio-Rad Laboratories, Redmond, Washington, United States).</p><p>Definitions of TB status included: ATBD, LTBI, and PTBD. ATBD status was based on acid-fast bacilli (AFB) sputum smear microscopy, which was performed by standard protocol (Ziehl-Neelsen staining), or Xpert MTB/RIF (Cepheid, Sunnyvale, California, United States). Patients with ATBD were newly diagnosed and had not initiated anti-TB treatment (or received &#x0003c;1 week of treatment). LTBI was diagnosed by QuantiFERON-TB Gold In-Tube (QFT-G; Cellestis Limited, Carnegie, Victoria, Australia). Blood samples were collected in QFT-G tubes, assayed according to manufacturer protocol and by enzyme-linked immunosorbent assay. Study enrollment was based on a positive QFT-G diagnostic result. PTBD was defined as having previous ATBD (pulmonary), anti-TB treatment, and post-treatment sputum conversion. PTBD patients received 6 months of anti-TB treatment for ATBD; study enrollment occurred between 2&#x02013;371 days after completing treatment. Controls were considered individuals with a negative QFT-G diagnostic result.</p></sec><sec id="sec005"><title>Sample collection and peripheral blood mononuclear cell isolation</title><p>Venous blood samples (8 mL) were collected in mononuclear cell preparation tubes (CPT<sup>&#x02122;</sup>; Becton Dickinson Vacutainer Systems; Franklin Lakes, New Jersey, United States), and processed per manufacturer&#x02019;s instructions.</p><p>Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples, based on manufacturer instructions (CPT<sup>&#x02122;</sup>; Becton Dickinson Vacutainer Systems; Franklin Lakes, New Jersey, United States). PBMCs were suspended at 5 x 10<sup>6</sup> cells/mL in cryopreservation medium (45% RPMI 1640, 45% fetal bovine serum, 10% dimethyl sulfoxide), and incubated overnight at -80&#x000b0;C (in Mr. Frosty<sup>&#x02122;</sup> freezing container; Nalgene, Rochester, New York, United States). PBMCs were stored in liquid nitrogen prior to analyses.</p></sec><sec id="sec006"><title><italic>Mycobacterium tuberculosis</italic> infection</title><p>Frozen PBMCs were thawed and incubated overnight (37&#x000b0;C in a 5% CO<sub>2</sub> humidified incubator) in growth media (RPMI 1640 [Gibco Laboratories; Grand Island, NY] with 2mM glutamine, 10% fetal bovine serum, 10mM 2-[4-[2-hydroxyethyl]-1-piperazinyl] ethanesulfonic acid, [Antibiotic-Antimycotic solution; Gibco Laboratories; Grand Island, New York, United States]). Cells (10<sup>6</sup>) were washed and re-suspended in fresh growth media containing 2 &#x003bc;g/ml whole cell lysate of <italic>M</italic>. <italic>tuberculosis</italic> strain H37Rv (<italic>Mycobacteria</italic> Research Laboratories at Colorado State University, Colorado, United States) for 48 hours (37&#x000b0;C in a 5% CO<sub>2</sub> humidified incubator). An initial pilot study standardized the lysate concentration required for stimulation.</p></sec><sec id="sec007"><title>Ribonucleic acid isolation</title><p>Total ribonucleic acid (RNA) was extracted (RNA Easy Plus Kit; Qiagen, Hilden, Germany) and quantitated (Qubit<sup>&#x000ae;</sup> 2.0 fluorometer; Life Technologies, Milan, Italy) for suppression subtractive hybridization (SSH). In two patient groups (ATBD, LTBI), 300 ng total RNA from each individual were pooled and quantified. Pooled total RNA (300 ng) was used for complementary deoxyribonucleic acid (cDNA) synthesis (SMARTer<sup>&#x02122;</sup> polymerase chain reaction [PCR] cDNA Synthesis Kit; Clontech Laboratories, Inc., Palo Alto, California, United States).</p></sec><sec id="sec008"><title>Complementary deoxyribonucleic acid subtractive libraries</title><p>SSH libraries were created with the PCR-select cDNA subtraction kit (Clontech Laboratories, Inc.; Palo Alto, California, United States), per the manufacturer instructions. In forward subtraction (ATBD-LTBI), cDNA from the ATBD group was the tester and LTBI was the driver. Conversely, in reverse subtraction (LTBI-ATBD), LTBI cDNA was the tester and ATBD cDNA was the driver. Real-time PCR (Rotor Gene 6000; Qiagen Inc., Hilden, Germany) amplified the subtracted, unsubtracted, and control cDNA with M13 primers. Following PCR (DNA amplification), products were cloned in the PCR 2.1-TA vector (Invitrogen, Carlsbad, California, United States) and transformed into <italic>Escherichia coli</italic> Top10 cells. From forward subtraction, approximately 200 clones were obtained; in reverse subtraction, about 150 clones were obtained. Subtraction efficiency was evaluated by comparing glyceraldehyde-3-phosphate dehydrogenase expression in the subtracted and unsubtracted cDNA.</p></sec><sec id="sec009"><title>Dot blot hybridization</title><p>PCR product (5 &#x003bc;l) were transferred to two nylon membranes. The two identical membranes were hybridized with a tester and driver probe. Digoxigenin (DIG)-labeled probes (DIG-High Prime Labelling and Detection kit; Roche Diagnostics; Mannheim, Germany) visualized hybridization by a color reaction. The detected (differentially expressed) clones were sequenced (ABI 3730 DNA Analyzer; Applied Biosystems, Foster City, California, United States). Sequences were compared with the National Center for Biotechnology Information (NCBI; National Institutes of Health) reference database (Basic Local Alignment Search Tool [BLAST]).</p></sec><sec id="sec010"><title>PCR quantification of gene expression</title><p>Gene expression of the identified sequences (from hybridization) were further assessed with real-time PCR (Rotor Gene 6000; Qiagen Inc., Hilden, Germany) in replicate. Primers were designed with NCBI Primer-BLAST (<xref ref-type="supplementary-material" rid="pone.0185640.s001">S1 Table</xref>). Each PCR reaction included: 0.3 &#x003bc;g cDNA, 200 nM primers, 12.5 &#x003bc;L 2x KAPA SYBR FAST quantitative polymerase chain reaction (qPCR; KAPA Biosystems; Boston, Massachusetts, United States). PCR cycling conditions were: 1 cycle (95&#x000b0;C for 3 minutes); 35 cycles (95&#x000b0;C for 30 seconds, 60&#x000b0;C for 1 minute). Human acidic ribosomal protein (HUPO) was the internal control gene. Cycle thresholds (C<sub>T</sub>) were calculated through the Rotor Gene software (version 1.7.87).</p></sec><sec id="sec011"><title>Statistical analysis</title><p>Relative gene expression was reported as fold-change, based on the comparative cycle threshold (2<sup>-&#x00394;&#x00394;CT</sup>) method [<xref rid="pone.0185640.ref022" ref-type="bibr">22</xref>] with HUPO as the internal control gene. Specifically:
<disp-formula id="pone.0185640.e001"><alternatives><graphic xlink:href="pone.0185640.e001.jpg" id="pone.0185640.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:msup><mml:mrow><mml:mtext>Fold-change</mml:mtext><mml:mspace width="2pt"/><mml:mo>=</mml:mo><mml:mspace width="2pt"/><mml:mn>2</mml:mn></mml:mrow><mml:mo>-</mml:mo></mml:msup><mml:msup><mml:mrow/><mml:mrow><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mtext>CT</mml:mtext></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
where
<disp-formula id="pone.0185640.e002"><alternatives><graphic xlink:href="pone.0185640.e002.jpg" id="pone.0185640.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mo>&#x00394;</mml:mo><mml:mtext>CT</mml:mtext></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msup><mml:mn>2</mml:mn><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mtext>CT</mml:mtext><mml:mspace width="1pt"/><mml:mtext>target</mml:mtext><mml:mspace width="1pt"/><mml:mtext>gene-CT</mml:mtext><mml:mspace width="1pt"/><mml:mtext>HUPO</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mspace width="1pt"/><mml:mspace width="1pt"/><mml:mtext>sample</mml:mtext><mml:mspace width="1pt"/><mml:mtext>A</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mtext>CT</mml:mtext><mml:mspace width="1pt"/><mml:mtext>target</mml:mtext><mml:mspace width="1pt"/><mml:mtext>gene</mml:mtext><mml:mspace width="1pt"/><mml:mtext>-</mml:mtext><mml:mspace width="1pt"/><mml:mtext>CT</mml:mtext><mml:mspace width="1pt"/><mml:mtext>HUPO</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mspace width="1pt"/><mml:mspace width="1pt"/><mml:mtext>sample</mml:mtext><mml:mspace width="1pt"/><mml:mtext>B</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula></p><p>[<xref rid="pone.0185640.ref022" ref-type="bibr">22</xref>]</p><p>For each comparison, fold-change was reported as the average of the fold-changes of the two replicates (<xref ref-type="table" rid="pone.0185640.t001">Table 1</xref>).</p><table-wrap id="pone.0185640.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185640.t001</object-id><label>Table 1</label><caption><title>Pairwise comparison groups<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref>.</title></caption><alternatives><graphic id="pone.0185640.t001g" xlink:href="pone.0185640.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="justify" rowspan="1" colspan="1">ATBD</td><td align="justify" rowspan="1" colspan="1">Controls</td></tr><tr><td align="justify" rowspan="1" colspan="1">LTBI</td><td align="justify" rowspan="1" colspan="1">Controls</td></tr><tr><td align="justify" rowspan="1" colspan="1">PTBD</td><td align="justify" rowspan="1" colspan="1">Controls</td></tr><tr><td align="justify" rowspan="1" colspan="1">ATBD</td><td align="justify" rowspan="1" colspan="1">LTBI</td></tr><tr><td align="justify" rowspan="1" colspan="1">ATBD</td><td align="justify" rowspan="1" colspan="1">PTBD</td></tr><tr><td align="justify" rowspan="1" colspan="1">LTBI</td><td align="justify" rowspan="1" colspan="1">PTBD</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><sup>a</sup>Abbreviations: active TB disease (ATBD), latent TB infection (LTBI), previous active TB disease (PTBD; after successful treatment)</p></fn></table-wrap-foot></table-wrap><p>For sociodemographic characteristics, the normality assumption of the age variable was assessed by the Kolmogorov-Smirnov test. Comparisons between the four study participant groups were evaluated by Kruskal-Wallis and Fisher&#x02019;s exact tests. Statistical analysis was conducted with SAS (version 9.4; SAS Institute, Inc., Cary, North Carolina, United States); statistical significance was based on alpha value &#x0003c; 0.05 and two-tailed tests.</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><sec id="sec013"><title>Study population</title><p>Among the study participants, 65.0% were male (<xref ref-type="table" rid="pone.0185640.t002">Table 2</xref>). The proportion of men differed across TB status (ATBD, LTBI, PTBD, controls) (p = 0.03). The median age was 31.5 years (interquartile range [IQR] 27.0&#x02013;40.5; <xref ref-type="table" rid="pone.0185640.t002">Table 2</xref>), and ranged between 18&#x02013;65 years. Median age was similar in the four study participant groups (p = 0.32).</p><table-wrap id="pone.0185640.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185640.t002</object-id><label>Table 2</label><caption><title>Study participant characteristics (n = 40)<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref>.</title></caption><alternatives><graphic id="pone.0185640.t002g" xlink:href="pone.0185640.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Males</bold>, n (%)</td><td align="center" rowspan="1" colspan="1">26 (65.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold> (years), median (IQR)</td><td align="center" rowspan="1" colspan="1">31.5 (27.0, 40.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TB</bold>, n (%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">ATBD <xref ref-type="table-fn" rid="t002fn002"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">10 (25.0)</td></tr><tr><td align="right" rowspan="1" colspan="1">LTBI <xref ref-type="table-fn" rid="t002fn003"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">10 (25.0)</td></tr><tr><td align="right" rowspan="1" colspan="1">PTBD <xref ref-type="table-fn" rid="t002fn004"><sup>d</sup></xref></td><td align="center" rowspan="1" colspan="1">10 (25.0)</td></tr><tr><td align="right" rowspan="1" colspan="1">No TB (control) <xref ref-type="table-fn" rid="t002fn005"><sup>e</sup></xref></td><td align="center" rowspan="1" colspan="1">10 (25.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a</sup>Abbreviations: active TB disease (ATBD), latent TB infection (LTBI), previous active TB disease (PTBD; after successful treatment).</p></fn><fn id="t002fn002"><p><sup>b</sup>Acid-fast bacilli [AFB] sputum smear microscopy</p></fn><fn id="t002fn003"><p><sup>c</sup>Individuals with a positive QuantiFERON Gold In-tube and negative AFB diagnostic</p></fn><fn id="t002fn004"><p><sup>d</sup>Individuals with previous ATBD who recently received anti-TB treatment for pulmonary TB (2&#x02013;371 days prior to study enrollment), and post-treatment sputum conversion (based on AFB)</p></fn><fn id="t002fn005"><p><sup>e</sup>Controls were considered individuals with negative QFT-G and AFB diagnostic results.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec014"><title>Active TB disease associated with increased cytokine gene expression</title><p>After <italic>M</italic>. <italic>tuberculosis</italic> infection, ATBD patient samples had increased gene expression of chemotactic factors (chemokine [C-X-C motif] ligand 1 [CXCL1], 3 [CXCL3], 8 [CXCL8 or interleukin [IL]-8]; chemokine [C-C motif] ligand 2 [CCL2; monocyte chemotactic protein [MCP]1; macrophage inflammatory protein [MIP] 1&#x003b1;] compared to controls (<xref ref-type="fig" rid="pone.0185640.g001">Fig 1</xref>, <xref ref-type="supplementary-material" rid="pone.0185640.s002">S2 Table</xref>). The fold-increases in chemokine expression were also greater among ATBD samples (2.7-fold CXCL1, 2.8-fold CXCL2, 3.1-fold CXCL3, 3.5-fold CXCL8, 2.2-fold CCL2, 1.6-fold MIP1&#x003b1;), compared to LTBI (<xref ref-type="fig" rid="pone.0185640.g001">Fig 1</xref>, <xref ref-type="supplementary-material" rid="pone.0185640.s003">S3 Table</xref>). In contrast, CCL8 (MCP2) gene expression was similar in comparing ATBD versus LTBI 1.1-fold (<xref ref-type="supplementary-material" rid="pone.0185640.s003">S3 Table</xref>).</p><fig id="pone.0185640.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185640.g001</object-id><label>Fig 1</label><caption><title>Relative gene expression among patients with ATBD, LTBI, PTBD, and controls<sup>a</sup>.</title><p><sup>a</sup> Abbreviations: active TB disease (ATBD), chemokine (C-X-C motif) ligand: (CXCL), cluster of differentiation (CD), ferritin light chain (FTL), gamma-interferon-inducible protein (IP30), interleukin (IL), latent TB infection (LTBI), mitogen activated protein kinase kinase (MAP2K), macrophage inflammatory protein (MIP), monocyte chemotactic protein (MCP), previous active TB disease (PTBD; after successful treatment), Ras-related nuclear protein (RAN).</p></caption><graphic xlink:href="pone.0185640.g001"/></fig><p>Relative to controls, ATBD was associated with higher gene expression of ILs (2.1-fold IL1B; <xref ref-type="fig" rid="pone.0185640.g001">Fig 1</xref>; <xref ref-type="supplementary-material" rid="pone.0185640.s002">S2 Table</xref>), which regulate the T helper 2 (Th2) response. In comparison to LTBI, ATBD samples had elevated IL1B (2.6-fold) and IL-12R (2.1-fold) gene expression (<xref ref-type="fig" rid="pone.0185640.g001">Fig 1</xref>).</p></sec><sec id="sec015"><title>Latent TB infection versus previous active TB disease</title><p>In comparing LTBI against PTBD groups, several chemotactic factors were elevated (1.7-fold CXCL2, 2.0-fold CXCL3, 1.7-fold CXCL8 [IL-8]) although others were similar (1.1-fold CCL2 [MCP1]; <xref ref-type="fig" rid="pone.0185640.g001">Fig 1</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec016"><title>Discussion</title><p>In summary, the gene expression profiles in ATBD, LTBI, PTBD, and control human study participants exhibit distinct patterns. These data provide a foundation for characterizing biomarker panels as correlates of protective immunity, which would serve as valuable surrogates in future development of TB vaccines and therapeutics.</p><p>Our findings are consistent with previous literature that observed elevated innate immune responses to <italic>M</italic>. <italic>tuberculosis</italic>, as well as <italic>M</italic>. <italic>tuberculosis</italic> evasion tactics in ATBD [<xref rid="pone.0185640.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0185640.ref028" ref-type="bibr">28</xref>]. Similar to our results, other studies have established the importance of cytokines (including constitutive and stimulated chemokine gene expression such as MCP-1, IL-8, MIP1&#x003b1;) in host protection against <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pone.0185640.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0185640.ref028" ref-type="bibr">28</xref>]. <italic>M</italic>. <italic>tuberculosis</italic> has been shown to induce IL1B in dendritic cells, which upregulates the host Th2 response and dampens the protective Th1 response [<xref rid="pone.0185640.ref023" ref-type="bibr">23</xref>].</p><p>Additionally, similar to our results other data indicated that the gene expression of chemokines (including MIP1&#x003b1;) may differ during ATBD. Studies have identified a role for microbial lipoproteins in stimulating cytokine production (such as IL-12) in macrophages (via Toll-like receptors) [<xref rid="pone.0185640.ref029" ref-type="bibr">29</xref>]. MIP has also been found to be present in infectious pathogens, such as <italic>Chlamydial trachomatis</italic> [<xref rid="pone.0185640.ref030" ref-type="bibr">30</xref>].</p><p>Broadly, other studies have also highlighted the potential of biomarker panels (including host protein biosignatures) as indicators of the immune response against <italic>M</italic>. <italic>tuberculosis</italic> that could have diagnostic and/or predictive value [<xref rid="pone.0185640.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0185640.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0185640.ref031" ref-type="bibr">31</xref>]. Furthermore, prior studies contend that differential gene expression was associated with increased risk of TB disease progression and relapse [<xref rid="pone.0185640.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0185640.ref019" ref-type="bibr">19</xref>]. One study with whole-blood microarray analysis reported differential gene expression between patients with ATBD and LTBI, and identified gene expression profiles associated with host control of <italic>M</italic>. <italic>tuberculosis</italic> (specifically apoptosis and natural killer cell activity) [<xref rid="pone.0185640.ref017" ref-type="bibr">17</xref>]. Two studies indicated that differential gene expression profiles could associate with TB relapse [<xref rid="pone.0185640.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0185640.ref019" ref-type="bibr">19</xref>]. These studies show that biomarker profiles have potential to be more robust than single biomarkers of TB immunity. Interferon (IFN)-gamma, for example, is perhaps the most utilized candidate TB biomarker for a protective immune response against <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pone.0185640.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0185640.ref035" ref-type="bibr">35</xref>]; however IFN-gamma has low accuracy and predictive power, especially as a biomarker of protection or disease outcome [<xref rid="pone.0185640.ref033" ref-type="bibr">33</xref>].</p><p>Our study has several limitations. Firstly, PBMCs were cryopreserved prior to <italic>M</italic>. <italic>tuberculosis</italic> stimulation and RNA extraction, which could affect transcriptional processes. Secondly, the interpretation of gene expression in biological function remains preliminary [<xref rid="pone.0185640.ref036" ref-type="bibr">36</xref>]. Additionally, given the use of 2<sup>-&#x00394;&#x00394;CT</sup> as a relative gene expression quantitation method [<xref rid="pone.0185640.ref022" ref-type="bibr">22</xref>], the findings need to be confirmed and extended with additional housekeeping controls [<xref rid="pone.0185640.ref037" ref-type="bibr">37</xref>]. Due to the pooling of samples in each group, there was no variance data, which restricted statistical analyses and corrections for multiple hypothesis testing. Further confirmatory studies could alternatively utilize groupwise comparisons.</p><p>Future studies are needed to elucidate the role of transcriptional signatures as immune correlates (including via single cell analysis [<xref rid="pone.0185640.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0185640.ref039" ref-type="bibr">39</xref>], prior to any claims that such profiles are predictive of clinical morbidities (ATBD, LTBI) and treatment outcomes. Studies to date have assessed cross-sectional data and therefore have not allowed for causal inference, which we could potentially address in a human cohort. Furthermore, studies need to account for other potential confounding factors, including the heterogeneity of patient immune response [<xref rid="pone.0185640.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0185640.ref041" ref-type="bibr">41</xref>]. Nonetheless, these data provide a useful platform in defining initial immunological themes that allow us to differentiate between human patients that fall into the active (ATBD), latent (LTBI), and active-treated (PTBD) disease classes.</p></sec><sec sec-type="supplementary-material" id="sec017"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0185640.s001"><label>S1 Table</label><caption><title>Primers in real-time PCR of differentially expressed genes.</title><p>(DOCX)</p></caption><media xlink:href="pone.0185640.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0185640.s002"><label>S2 Table</label><caption><title>Relative gene expression among patients with ATBD, LTBI, PTBD, compared to controls.</title><p>(DOCX)</p></caption><media xlink:href="pone.0185640.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0185640.s003"><label>S3 Table</label><caption><title>Relative gene expression among patients with ATBD, compared to LTBI.</title><p>(DOCX)</p></caption><media xlink:href="pone.0185640.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0185640.ref001"><label>1</label><mixed-citation publication-type="other">World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization; 2016.</mixed-citation></ref><ref id="pone.0185640.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Cox</surname><given-names>HS</given-names></name>, <name><surname>Morrow</surname><given-names>M</given-names></name>, <name><surname>Deutschmann</surname><given-names>PW</given-names></name>. <article-title>Long term efficacy of DOTS regimens for tuberculosis: systematic review</article-title>. <source>BMJ</source>. <year>2008</year>;<volume>336</volume>(<issue>7642</issue>):<fpage>484</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.39463.640787.BE">10.1136/bmj.39463.640787.BE</ext-link></comment>
<?supplied-pmid 18250104?><pub-id pub-id-type="pmid">18250104</pub-id></mixed-citation></ref><ref id="pone.0185640.ref003"><label>3</label><mixed-citation publication-type="book"><collab>World Health Organization and International Union Against Tuberculosis and Lung Disease (WHO/Union) Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2002&#x02013;2007</collab>. <source>Anti-tuberculosis drug resistance in the world: fourth global report</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="pone.0185640.ref004"><label>4</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source>Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="pone.0185640.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>M-L</given-names></name>, <name><surname>Hasker</surname><given-names>E</given-names></name>, <name><surname>Van Deun</surname><given-names>A</given-names></name>, <name><surname>Roberfroid</surname><given-names>D</given-names></name>, <name><surname>Boelaert</surname><given-names>M</given-names></name>, <name><surname>Van der Stuyft</surname><given-names>P</given-names></name>. <article-title>Recurrence in tuberculosis: relapse or reinfection?</article-title>
<source>Lancet Infect Dis</source>. <year>2003</year>;<volume>3</volume>(<issue>5</issue>):<fpage>282</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 12726976?><pub-id pub-id-type="pmid">12726976</pub-id></mixed-citation></ref><ref id="pone.0185640.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>SH</given-names></name>. <article-title>Fact and fiction in tuberculosis vaccine research: 10 years later</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>(<issue>8</issue>):<fpage>633</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1473-3099(11)70146-3">10.1016/S1473-3099(11)70146-3</ext-link></comment>
<?supplied-pmid 21798463?><pub-id pub-id-type="pmid">21798463</pub-id></mixed-citation></ref><ref id="pone.0185640.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Kaufmann</surname><given-names>SH</given-names></name>, <name><surname>Hussey</surname><given-names>G</given-names></name>, <name><surname>Lambert</surname><given-names>P-H</given-names></name>. <article-title>New vaccines for tuberculosis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9731</issue>):<fpage>2110</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(10)60393-5">10.1016/S0140-6736(10)60393-5</ext-link></comment>
<?supplied-pmid 20488515?><pub-id pub-id-type="pmid">20488515</pub-id></mixed-citation></ref><ref id="pone.0185640.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>DG</given-names></name>, <name><surname>Barry</surname><given-names>CE</given-names><suffix>3rd</suffix></name>, <name><surname>Flynn</surname><given-names>JL</given-names></name>. <article-title>Tuberculosis: what we don't know can, and does, hurt us</article-title>. <source>Science</source>. <year>2010</year>;<volume>328</volume>(<issue>5980</issue>):<fpage>852</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1184784">10.1126/science.1184784</ext-link></comment>
<?supplied-pmid 20466922?><pub-id pub-id-type="pmid">20466922</pub-id></mixed-citation></ref><ref id="pone.0185640.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Doherty</surname><given-names>TM</given-names></name>, <name><surname>Dietrich</surname><given-names>J</given-names></name>, <name><surname>Billeskov</surname><given-names>R</given-names></name>. <article-title>Tuberculosis subunit vaccines: from basic science to clinical testing</article-title>. <source>Exp Opin Biol Ther</source>. <year>2007</year>;<volume>7</volume>(<issue>10</issue>):<fpage>1539</fpage>&#x02013;<lpage>49</lpage>.</mixed-citation></ref><ref id="pone.0185640.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>MY</given-names></name>, <name><surname>Ottenhoff</surname><given-names>TH</given-names></name>. <article-title>Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent <italic>Mycobacterium tuberculosis</italic> infection</article-title>. <source>Biol Chem</source>. <year>2008</year>;<volume>389</volume>(<issue>5</issue>):<fpage>497</fpage>&#x02013;<lpage>511</lpage>. <?supplied-pmid 18953716?><pub-id pub-id-type="pmid">18953716</pub-id></mixed-citation></ref><ref id="pone.0185640.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Walzl</surname><given-names>G</given-names></name>, <name><surname>Ronacher</surname><given-names>K</given-names></name>, <name><surname>Hanekom</surname><given-names>W</given-names></name>, <name><surname>Scriba</surname><given-names>TJ</given-names></name>, <name><surname>Zumla</surname><given-names>A</given-names></name>. <article-title>Immunological biomarkers of tuberculosis</article-title>. <source>Nat Rev Immunol</source>. <year>2011</year>;<volume>11</volume>(<issue>5</issue>):<fpage>343</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri2960">10.1038/nri2960</ext-link></comment>
<?supplied-pmid 21475309?><pub-id pub-id-type="pmid">21475309</pub-id></mixed-citation></ref><ref id="pone.0185640.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Petruccioli</surname><given-names>E</given-names></name>, <name><surname>Scriba</surname><given-names>TJ</given-names></name>, <name><surname>Petrone</surname><given-names>L</given-names></name>, <name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Cirillo</surname><given-names>DM</given-names></name>, <name><surname>Joosten</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis</article-title>. <source>Eur Respir J</source>. <year>2016</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1751</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1183/13993003.01012-2016">10.1183/13993003.01012-2016</ext-link></comment>
<?supplied-pmid 27836953?><pub-id pub-id-type="pmid">27836953</pub-id></mixed-citation></ref><ref id="pone.0185640.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Jacobsen</surname><given-names>M</given-names></name>, <name><surname>Mattow</surname><given-names>J</given-names></name>, <name><surname>Repsilber</surname><given-names>D</given-names></name>, <name><surname>Kaufmann</surname><given-names>SH</given-names></name>. <article-title>Novel strategies to identify biomarkers in tuberculosis</article-title>. <source>Biol Chem</source>. <year>2008</year>;<volume>389</volume>(<issue>5</issue>):<fpage>487</fpage>&#x02013;<lpage>95</lpage>. <?supplied-pmid 18953715?><pub-id pub-id-type="pmid">18953715</pub-id></mixed-citation></ref><ref id="pone.0185640.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Doherty</surname><given-names>TM</given-names></name>, <name><surname>Wallis</surname><given-names>RS</given-names></name>, <name><surname>Zumla</surname><given-names>A</given-names></name>. <article-title>Biomarkers of disease activity, cure, and relapse in tuberculosis</article-title>. <source>Clin Chest Med</source>. <year>2009</year>;<volume>30</volume>(<issue>4</issue>):<fpage>783</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ccm.2009.08.008">10.1016/j.ccm.2009.08.008</ext-link></comment>
<?supplied-pmid 19925967?><pub-id pub-id-type="pmid">19925967</pub-id></mixed-citation></ref><ref id="pone.0185640.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Doherty</surname><given-names>M</given-names></name>, <name><surname>Wallis</surname><given-names>RS</given-names></name>, <name><surname>Zumla</surname><given-names>A</given-names></name>. <article-title>Biomarkers for tuberculosis disease status and diagnosis</article-title>. <source>Curr Opin Pulm Med</source>. <year>2009</year>;<volume>15</volume>(<issue>3</issue>):<fpage>181</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 19396972?><pub-id pub-id-type="pmid">19396972</pub-id></mixed-citation></ref><ref id="pone.0185640.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Berry</surname><given-names>MP</given-names></name>, <name><surname>Graham</surname><given-names>CM</given-names></name>, <name><surname>McNab</surname><given-names>FW</given-names></name>, <name><surname>Xu</surname><given-names>Z</given-names></name>, <name><surname>Bloch</surname><given-names>SA</given-names></name>, <name><surname>Oni</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title>. <source>Nature</source>. <year>2010</year>;<volume>466</volume>(<issue>7309</issue>):<fpage>973</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature09247">10.1038/nature09247</ext-link></comment>
<?supplied-pmid 20725040?><pub-id pub-id-type="pmid">20725040</pub-id></mixed-citation></ref><ref id="pone.0185640.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Maertzdorf</surname><given-names>J</given-names></name>, <name><surname>Repsilber</surname><given-names>D</given-names></name>, <name><surname>Parida</surname><given-names>SK</given-names></name>, <name><surname>Stanley</surname><given-names>K</given-names></name>, <name><surname>Roberts</surname><given-names>T</given-names></name>, <name><surname>Black</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Human gene expression profiles of susceptibility and resistance in tuberculosis</article-title>. <source>Genes Immun</source>. <year>2011</year>;<volume>12</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/gene.2010.51">10.1038/gene.2010.51</ext-link></comment>
<?supplied-pmid 20861863?><pub-id pub-id-type="pmid">20861863</pub-id></mixed-citation></ref><ref id="pone.0185640.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Mistry</surname><given-names>R</given-names></name>, <name><surname>Cliff</surname><given-names>JM</given-names></name>, <name><surname>Clayton</surname><given-names>CL</given-names></name>, <name><surname>Beyers</surname><given-names>N</given-names></name>, <name><surname>Mohamed</surname><given-names>YS</given-names></name>, <name><surname>Wilson</surname><given-names>PA</given-names></name>, <etal>et al</etal>
<article-title>Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis</article-title>. <source>J Infect Dis</source>. <year>2007</year>;<volume>195</volume>(<issue>3</issue>):<fpage>357</fpage>&#x02013;<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/510397">10.1086/510397</ext-link></comment>
<?supplied-pmid 17205474?><pub-id pub-id-type="pmid">17205474</pub-id></mixed-citation></ref><ref id="pone.0185640.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Cliff</surname><given-names>JM</given-names></name>, <name><surname>Cho</surname><given-names>JE</given-names></name>, <name><surname>Lee</surname><given-names>JS</given-names></name>, <name><surname>Ronacher</surname><given-names>K</given-names></name>, <name><surname>King</surname><given-names>EC</given-names></name>, <name><surname>van Helden</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment</article-title>. <source>J Infect Dis</source>. <year>2016</year>;<volume>213</volume>(<issue>3</issue>):<fpage>485</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jiv447">10.1093/infdis/jiv447</ext-link></comment>
<?supplied-pmid 26351358?><pub-id pub-id-type="pmid">26351358</pub-id></mixed-citation></ref><ref id="pone.0185640.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Parida</surname><given-names>SK</given-names></name>, <name><surname>Kaufmann</surname><given-names>SH</given-names></name>. <article-title>The quest for biomarkers in tuberculosis</article-title>. <source>Drug Discov Today</source>. <year>2010</year>;<volume>15</volume>(<issue>3</issue>):<fpage>148</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">19854295</pub-id></mixed-citation></ref><ref id="pone.0185640.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>Z</given-names></name>, <name><surname>Lienhardt</surname><given-names>C</given-names></name>, <name><surname>McIlleron</surname><given-names>H</given-names></name>, <name><surname>Nunn</surname><given-names>AJ</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>. <article-title>Global tuberculosis drug development pipeline: the need and the reality</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9731</issue>):<fpage>2100</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(10)60359-9">10.1016/S0140-6736(10)60359-9</ext-link></comment>
<?supplied-pmid 20488518?><pub-id pub-id-type="pmid">20488518</pub-id></mixed-citation></ref><ref id="pone.0185640.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Schmittgen</surname><given-names>TD</given-names></name>, <name><surname>Livak</surname><given-names>KJ</given-names></name>. <article-title>Analyzing real-time PCR data by the comparative CT method</article-title>. <source>Nat Protoc</source>. <year>2008</year>;<volume>3</volume>(<issue>6</issue>):<fpage>1101</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 18546601?><pub-id pub-id-type="pmid">18546601</pub-id></mixed-citation></ref><ref id="pone.0185640.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Dwivedi</surname><given-names>VP</given-names></name>, <name><surname>Bhattacharya</surname><given-names>D</given-names></name>, <name><surname>Chatterjee</surname><given-names>S</given-names></name>, <name><surname>Prasad</surname><given-names>DV</given-names></name>, <name><surname>Chattopadhyay</surname><given-names>D</given-names></name>, <name><surname>Van Kaer</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title><italic>Mycobacterium tuberculosis</italic> directs T helper 2 cell differentiation by inducing interleukin-1beta production in dendritic cells</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>40</issue>):<fpage>33656</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M112.375154">10.1074/jbc.M112.375154</ext-link></comment>
<?supplied-pmid 22810226?><pub-id pub-id-type="pmid">22810226</pub-id></mixed-citation></ref><ref id="pone.0185640.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Ferrero</surname><given-names>E</given-names></name>, <name><surname>Biswas</surname><given-names>P</given-names></name>, <name><surname>Vettoretto</surname><given-names>K</given-names></name>, <name><surname>Ferrarini</surname><given-names>M</given-names></name>, <name><surname>Uguccioni</surname><given-names>M</given-names></name>, <name><surname>Piali</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Macrophages exposed to <italic>Mycobacterium tuberculosis</italic> release chemokines able to recruit selected leucocyte subpopulations: focus on gamma delta cells</article-title>. <source>Immunology</source>. <year>2003</year>;<volume>108</volume>(<issue>3</issue>):<fpage>365</fpage>&#x02013;<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1365-2567.2003.01600.x">10.1046/j.1365-2567.2003.01600.x</ext-link></comment>
<?supplied-pmid 12603603?><pub-id pub-id-type="pmid">12603603</pub-id></mixed-citation></ref><ref id="pone.0185640.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Monin</surname><given-names>L</given-names></name>, <name><surname>Khader</surname><given-names>SA</given-names></name>. <article-title>Chemokines in tuberculosis: the good, the bad and the ugly</article-title>. <source>Semin Immunol</source>. <year>2014</year>;<volume>26</volume>(<issue>6</issue>):<fpage>552</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.smim.2014.09.004">10.1016/j.smim.2014.09.004</ext-link></comment>
<?supplied-pmid 25444549?><pub-id pub-id-type="pmid">25444549</pub-id></mixed-citation></ref><ref id="pone.0185640.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Rhoades</surname><given-names>ER</given-names></name>, <name><surname>Cooper</surname><given-names>AM</given-names></name>, <name><surname>Orme</surname><given-names>IM</given-names></name>. <article-title>Chemokine response in mice infected with <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Infect Immun</source>. <year>1995</year>;<volume>63</volume>(<issue>10</issue>):<fpage>3871</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 7558294?><pub-id pub-id-type="pmid">7558294</pub-id></mixed-citation></ref><ref id="pone.0185640.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Strieter</surname><given-names>RM</given-names></name>, <name><surname>Belperio</surname><given-names>JA</given-names></name>, <name><surname>Keane</surname><given-names>MP</given-names></name>. <article-title>Cytokines in innate host defense in the lung</article-title>. <source>J Clin Invest</source>. <year>2002</year>;<volume>109</volume>(<issue>6</issue>):<fpage>699</fpage>&#x02013;<lpage>705</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI15277">10.1172/JCI15277</ext-link></comment>
<?supplied-pmid 11901175?><pub-id pub-id-type="pmid">11901175</pub-id></mixed-citation></ref><ref id="pone.0185640.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Bowdish</surname><given-names>DM</given-names></name>, <name><surname>Sakamoto</surname><given-names>K</given-names></name>, <name><surname>Kim</surname><given-names>MJ</given-names></name>, <name><surname>Kroos</surname><given-names>M</given-names></name>, <name><surname>Mukhopadhyay</surname><given-names>S</given-names></name>, <name><surname>Leifer</surname><given-names>CA</given-names></name>, <etal>et al</etal>
<article-title>MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and <italic>Mycobacterium tuberculosis</italic></article-title>. <source>PLoS Pathog</source>. <year>2009</year>;<volume>5</volume>(<issue>6</issue>):<fpage>e1000474</fpage> Epub 2009/06/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1000474">10.1371/journal.ppat.1000474</ext-link></comment>
<?supplied-pmid 19521507?><pub-id pub-id-type="pmid">19521507</pub-id></mixed-citation></ref><ref id="pone.0185640.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Brightbill</surname><given-names>HD</given-names></name>, <name><surname>Libraty</surname><given-names>DH</given-names></name>, <name><surname>Krutzik</surname><given-names>SR</given-names></name>, <name><surname>Yang</surname><given-names>RB</given-names></name>, <name><surname>Belisle</surname><given-names>JT</given-names></name>, <name><surname>Bleharski</surname><given-names>JR</given-names></name>, <etal>et al</etal>
<article-title>Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors</article-title>. <source>Science</source>. <year>1999</year>;<volume>285</volume>(<issue>5428</issue>):<fpage>732</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 10426995?><pub-id pub-id-type="pmid">10426995</pub-id></mixed-citation></ref><ref id="pone.0185640.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Neff</surname><given-names>L</given-names></name>, <name><surname>Daher</surname><given-names>S</given-names></name>, <name><surname>Muzzin</surname><given-names>P</given-names></name>, <name><surname>Spenato</surname><given-names>U</given-names></name>, <name><surname>Gulacar</surname><given-names>F</given-names></name>, <name><surname>Gabay</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Molecular characterization and subcellular localization of macrophage infectivity potentiator, a Chlamydia trachomatis lipoprotein</article-title>. <source>J Bacteriol</source>. <year>2007</year>;<volume>189</volume>(<issue>13</issue>):<fpage>4739</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JB.01889-06">10.1128/JB.01889-06</ext-link></comment>
<?supplied-pmid 17449608?><pub-id pub-id-type="pmid">17449608</pub-id></mixed-citation></ref><ref id="pone.0185640.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Achkar</surname><given-names>JM</given-names></name>, <name><surname>Cortes</surname><given-names>L</given-names></name>, <name><surname>Croteau</surname><given-names>P</given-names></name>, <name><surname>Yanofsky</surname><given-names>C</given-names></name>, <name><surname>Mentinova</surname><given-names>M</given-names></name>, <name><surname>Rajotte</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Host protein biomarkers identify active tuberculosis in HIV uninfected and co-infected individuals</article-title>. <source>EBioMedicine</source>. <year>2015</year>;<volume>2</volume>(<issue>9</issue>):<fpage>1160</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ebiom.2015.07.039">10.1016/j.ebiom.2015.07.039</ext-link></comment>
<?supplied-pmid 26501113?><pub-id pub-id-type="pmid">26501113</pub-id></mixed-citation></ref><ref id="pone.0185640.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Flynn</surname><given-names>JL</given-names></name>, <name><surname>Chan</surname><given-names>J</given-names></name>, <name><surname>Triebold</surname><given-names>KJ</given-names></name>, <name><surname>Dalton</surname><given-names>DK</given-names></name>, <name><surname>Stewart</surname><given-names>TA</given-names></name>, <name><surname>Bloom</surname><given-names>BR</given-names></name>. <article-title>An essential role for interferon gamma in resistance to <italic>Mycobacterium tuberculosis</italic> infection</article-title>. <source>J Exp Med</source>. <year>1993</year>;<volume>178</volume>(<issue>6</issue>):<fpage>2249</fpage>&#x02013;<lpage>54</lpage>. <?supplied-pmid 7504064?><pub-id pub-id-type="pmid">7504064</pub-id></mixed-citation></ref><ref id="pone.0185640.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Mazurek</surname><given-names>GH</given-names></name>, <name><surname>Jereb</surname><given-names>J</given-names></name>, <name><surname>Vernon</surname><given-names>A</given-names></name>, <name><surname>LoBue</surname><given-names>P</given-names></name>, <name><surname>Goldberg</surname><given-names>S</given-names></name>, <name><surname>Castro</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Updated guidelines for using interferon gamma release assays to detect <italic>Mycobacterium tuberculosis</italic> infection-United States, 2010</article-title>. <source>MMWR Recomm Rep</source>. <year>2010</year>;<volume>59</volume>(<issue>RR-5</issue>):<fpage>1</fpage>&#x02013;<lpage>25</lpage>. <?supplied-pmid 20577159?><pub-id pub-id-type="pmid">20577159</pub-id></mixed-citation></ref><ref id="pone.0185640.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>AM</given-names></name>, <name><surname>Dalton</surname><given-names>DK</given-names></name>, <name><surname>Stewart</surname><given-names>TA</given-names></name>, <name><surname>Griffin</surname><given-names>JP</given-names></name>, <name><surname>Russell</surname><given-names>DG</given-names></name>, <name><surname>Orme</surname><given-names>IM</given-names></name>. <article-title>Disseminated tuberculosis in interferon gamma gene-disrupted mice</article-title>. <source>J Exp Med</source>. <year>1993</year>;<volume>178</volume>(<issue>6</issue>):<fpage>2243</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 8245795?><pub-id pub-id-type="pmid">8245795</pub-id></mixed-citation></ref><ref id="pone.0185640.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Goletti</surname><given-names>D</given-names></name>, <name><surname>Sanduzzi</surname><given-names>A</given-names></name>, <name><surname>Delogu</surname><given-names>G</given-names></name>. <article-title>Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches</article-title>. <source>J Rheumatol Suppl</source>. <year>2014</year>;<volume>91</volume>:<fpage>24</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3899/jrheum.140099">10.3899/jrheum.140099</ext-link></comment>
<?supplied-pmid 24788997?><pub-id pub-id-type="pmid">24788997</pub-id></mixed-citation></ref><ref id="pone.0185640.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>A</given-names></name>, <name><surname>Tamayo</surname><given-names>P</given-names></name>, <name><surname>Mootha</surname><given-names>VK</given-names></name>, <name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <name><surname>Gillette</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>;<volume>102</volume>(<issue>43</issue>):<fpage>15545</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0506580102">10.1073/pnas.0506580102</ext-link></comment>
<?supplied-pmid 16199517?><pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation></ref><ref id="pone.0185640.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Thellin</surname><given-names>O</given-names></name>, <name><surname>Zorzi</surname><given-names>W</given-names></name>, <name><surname>Lakaye</surname><given-names>B</given-names></name>, <name><surname>De Borman</surname><given-names>B</given-names></name>, <name><surname>Coumans</surname><given-names>B</given-names></name>, <name><surname>Hennen</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Housekeeping genes as internal standards: use and limits</article-title>. <source>J Biotechnol</source>. <year>1999</year>;<volume>75</volume>(<issue>2&#x02013;3</issue>):<fpage>291</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 10617337?><pub-id pub-id-type="pmid">10617337</pub-id></mixed-citation></ref><ref id="pone.0185640.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Fritzsch</surname><given-names>FS</given-names></name>, <name><surname>Dusny</surname><given-names>C</given-names></name>, <name><surname>Frick</surname><given-names>O</given-names></name>, <name><surname>Schmid</surname><given-names>A</given-names></name>. <article-title>Single-cell analysis in biotechnology, systems biology, and biocatalysis</article-title>. <source>Annu Rev Chem Biomol Eng</source>. <year>2012</year>;<volume>3</volume>:<fpage>129</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1146/annurev-chembioeng-062011-081056">10.1146/annurev-chembioeng-062011-081056</ext-link></comment>
<?supplied-pmid 22468600?><pub-id pub-id-type="pmid">22468600</pub-id></mixed-citation></ref><ref id="pone.0185640.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Rubakhin</surname><given-names>SS</given-names></name>, <name><surname>Romanova</surname><given-names>EV</given-names></name>, <name><surname>Nemes</surname><given-names>P</given-names></name>, <name><surname>Sweedler</surname><given-names>JV</given-names></name>. <article-title>Profiling metabolites and peptides in single cells</article-title>. <source>Nat Methods</source>. <year>2011</year>;<volume>8</volume>(<issue>4s</issue>):<fpage>S20</fpage>&#x02013;<lpage>S9</lpage>.<pub-id pub-id-type="pmid">21451513</pub-id></mixed-citation></ref><ref id="pone.0185640.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>W-L</given-names></name>, <name><surname>Perng</surname><given-names>W-C</given-names></name>, <name><surname>Huang</surname><given-names>C-H</given-names></name>, <name><surname>Yang</surname><given-names>C-Y</given-names></name>, <name><surname>Wu</surname><given-names>C-P</given-names></name>, <name><surname>Chen</surname><given-names>J-H</given-names></name>. <article-title>Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1&#x003b2; (IL-1&#x003b2;) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis</article-title>. <source>Clin Vaccine Immunol</source>. <year>2010</year>;<volume>17</volume>(<issue>2</issue>):<fpage>223</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00381-09">10.1128/CVI.00381-09</ext-link></comment>
<?supplied-pmid 20007364?><pub-id pub-id-type="pmid">20007364</pub-id></mixed-citation></ref><ref id="pone.0185640.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Barry</surname><given-names>CE</given-names></name>, <name><surname>Boshoff</surname><given-names>HI</given-names></name>, <name><surname>Dartois</surname><given-names>V</given-names></name>, <name><surname>Dick</surname><given-names>T</given-names></name>, <name><surname>Ehrt</surname><given-names>S</given-names></name>, <name><surname>Flynn</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</article-title>. <source>Nat Rev Microbiol</source>. <year>2009</year>;<volume>7</volume>(<issue>12</issue>):<fpage>845</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrmicro2236">10.1038/nrmicro2236</ext-link></comment>
<?supplied-pmid 19855401?><pub-id pub-id-type="pmid">19855401</pub-id></mixed-citation></ref></ref-list></back></article>